Literature DB >> 28819678

[Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy].

L-M Krabbe1,2, B Krabbe3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28819678     DOI： 10.1007/s00120-017-0489-y

Source DB:  PubMed          Journal:  Urologe A        ISSN： 0340-2592            Impact factor:   0.639


× No keyword cloud information.
  23 in total

1.  PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma.

Authors:  J R Perry; J A Julian; N J Laperriere; W Geerts; G Agnelli; L R Rogers; M G Malkin; R Sawaya; R Baker; A Falanga; S Parpia; T Finch; M N Levine
Journal:  J Thromb Haemost       Date:  2010-09       Impact factor: 5.824

2.  Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial.

Authors:  Kostandinos Sideras; Paul L Schaefer; Scott H Okuno; Jeff A Sloan; Leila Kutteh; Tom R Fitch; Shaker R Dakhil; Ralph Levitt; Steven R Alberts; Roscoe F Morton; Kendrith M Rowland; Paul J Novotny; Charles L Loprinzi
Journal:  Mayo Clin Proc       Date:  2006-06       Impact factor: 7.616

3.  Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial.

Authors:  Alok A Khorana; Charles W Francis; Nicole M Kuderer; Marc Carrier; Thomas L Ortel; Ted Wun; Deborah Rubens; Susan Hobbs; Renuka Iyer; Derick Peterson; Andrea Baran; Katherine Kaproth-Joslin; Gary H Lyman
Journal:  Thromb Res       Date:  2017-01-26       Impact factor: 3.944

4.  Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer.

Authors:  A Maraveyas; J Waters; R Roy; D Fyfe; D Propper; F Lofts; J Sgouros; E Gardiner; K Wedgwood; C Ettelaie; G Bozas
Journal:  Eur J Cancer       Date:  2011-11-17       Impact factor: 9.162

5.  Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer.

Authors:  Giancarlo Agnelli; Daniel J George; Ajay K Kakkar; William Fisher; Michael R Lassen; Patrick Mismetti; Patrick Mouret; Umesh Chaudhari; Francesca Lawson; Alexander G G Turpie
Journal:  N Engl J Med       Date:  2012-02-16       Impact factor: 91.245

6.  Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer.

Authors:  Frederiek F van Doormaal; Marcello Di Nisio; Hans-Martin Otten; Dick J Richel; Martin Prins; Harry R Buller
Journal:  J Clin Oncol       Date:  2011-04-18       Impact factor: 44.544

7.  The effect of low molecular weight heparin on survival in patients with advanced malignancy.

Authors:  Clara P W Klerk; Susanne M Smorenburg; Hans-Martin Otten; Anthonie W A Lensing; Martin H Prins; Franco Piovella; Paolo Prandoni; Monique M E M Bos; Dick J Richel; Geertjan van Tienhoven; Harry R Büller
Journal:  J Clin Oncol       Date:  2005-02-07       Impact factor: 44.544

8.  Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS).

Authors:  Ajay K Kakkar; Mark N Levine; Zbigniew Kadziola; Nicholas R Lemoine; Vanessa Low; Heman K Patel; Gordon Rustin; Michael Thomas; Mary Quigley; Robin C N Williamson
Journal:  J Clin Oncol       Date:  2004-05-15       Impact factor: 44.544

9.  A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer.

Authors:  M Altinbas; H S Coskun; O Er; M Ozkan; B Eser; A Unal; M Cetin; S Soyuer
Journal:  J Thromb Haemost       Date:  2004-08       Impact factor: 5.824

10.  Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study.

Authors:  Giancarlo Agnelli; Gualberto Gussoni; Carlo Bianchini; Melina Verso; Mario Mandalà; Luigi Cavanna; Sandro Barni; Roberto Labianca; Franco Buzzi; Giovanni Scambia; Rodolfo Passalacqua; Sergio Ricci; Giampietro Gasparini; Vito Lorusso; Erminio Bonizzoni; Maurizio Tonato
Journal:  Lancet Oncol       Date:  2009-08-31       Impact factor: 41.316
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.